 Nalu Navarro Alvarez
Concepts (318)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatocytes | 22 | 2016 | 217 | 2.430 |
Why?
| | Liver Transplantation | 13 | 2023 | 841 | 2.320 |
Why?
| | Transplantation, Heterologous | 13 | 2020 | 195 | 2.200 |
Why?
| | Acute-On-Chronic Liver Failure | 4 | 2023 | 7 | 1.890 |
Why?
| | Liver Diseases | 7 | 2022 | 300 | 1.590 |
Why?
| | Liver Regeneration | 7 | 2022 | 47 | 1.340 |
Why?
| | Liver Failure | 5 | 2018 | 86 | 1.110 |
Why?
| | Graft Rejection | 5 | 2020 | 571 | 1.080 |
Why?
| | Swine | 15 | 2018 | 778 | 1.000 |
Why?
| | Galectins | 2 | 2022 | 24 | 0.930 |
Why?
| | Embryonic Stem Cells | 8 | 2009 | 129 | 0.920 |
Why?
| | Galectin 3 | 3 | 2022 | 19 | 0.880 |
Why?
| | CD47 Antigen | 3 | 2016 | 38 | 0.860 |
Why?
| | Blood Coagulation Factors | 5 | 2020 | 54 | 0.830 |
Why?
| | Papio | 6 | 2018 | 96 | 0.830 |
Why?
| | Hepatitis, Alcoholic | 1 | 2022 | 13 | 0.760 |
Why?
| | Heterografts | 2 | 2020 | 135 | 0.760 |
Why?
| | Cell Culture Techniques | 9 | 2009 | 359 | 0.700 |
Why?
| | Blood Component Removal | 2 | 2018 | 27 | 0.690 |
Why?
| | Tissue Engineering | 8 | 2022 | 422 | 0.680 |
Why?
| | Graft Survival | 8 | 2020 | 523 | 0.670 |
Why?
| | Models, Animal | 3 | 2020 | 384 | 0.590 |
Why?
| | Islets of Langerhans Transplantation | 4 | 2008 | 64 | 0.570 |
Why?
| | Liver | 13 | 2022 | 1867 | 0.560 |
Why?
| | Betacoronavirus | 1 | 2020 | 268 | 0.540 |
Why?
| | Liver Cirrhosis | 5 | 2023 | 309 | 0.540 |
Why?
| | Bone Marrow Transplantation | 2 | 2015 | 287 | 0.500 |
Why?
| | Antigens, Heterophile | 1 | 2015 | 5 | 0.480 |
Why?
| | Animals | 50 | 2022 | 36882 | 0.470 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 367 | 0.470 |
Why?
| | Coronavirus Infections | 1 | 2020 | 365 | 0.470 |
Why?
| | Thrombocytopenia | 2 | 2016 | 197 | 0.450 |
Why?
| | Immunity, Humoral | 1 | 2015 | 117 | 0.440 |
Why?
| | Inflammation | 3 | 2022 | 2831 | 0.430 |
Why?
| | Stem Cells | 4 | 2016 | 595 | 0.430 |
Why?
| | Prognosis | 4 | 2022 | 3931 | 0.410 |
Why?
| | Gene Deletion | 2 | 2013 | 390 | 0.400 |
Why?
| | Peptides | 3 | 2010 | 975 | 0.390 |
Why?
| | Swine, Miniature | 3 | 2018 | 88 | 0.390 |
Why?
| | Islets of Langerhans | 5 | 2008 | 793 | 0.390 |
Why?
| | Pandemics | 1 | 2020 | 1630 | 0.360 |
Why?
| | Liver Failure, Acute | 6 | 2015 | 65 | 0.360 |
Why?
| | Bone Marrow Cells | 2 | 2010 | 316 | 0.350 |
Why?
| | Hemorrhage | 1 | 2016 | 717 | 0.350 |
Why?
| | Cell Differentiation | 11 | 2010 | 1985 | 0.350 |
Why?
| | Blood Proteins | 2 | 2022 | 245 | 0.320 |
Why?
| | B-Lymphocytes | 1 | 2015 | 845 | 0.320 |
Why?
| | Hepatectomy | 6 | 2018 | 229 | 0.320 |
Why?
| | Biomarkers | 6 | 2022 | 4095 | 0.310 |
Why?
| | Animals, Genetically Modified | 4 | 2018 | 244 | 0.310 |
Why?
| | Cell Separation | 1 | 2010 | 314 | 0.300 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2008 | 193 | 0.300 |
Why?
| | Tissue Scaffolds | 2 | 2009 | 209 | 0.300 |
Why?
| | Phagocytosis | 1 | 2011 | 385 | 0.300 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 295 | 0.290 |
Why?
| | Glycoproteins | 1 | 2010 | 356 | 0.290 |
Why?
| | Colonic Neoplasms | 1 | 2010 | 250 | 0.280 |
Why?
| | Cell Transplantation | 4 | 2010 | 38 | 0.270 |
Why?
| | Antigens, CD | 1 | 2010 | 527 | 0.270 |
Why?
| | Fibronectins | 1 | 2008 | 130 | 0.270 |
Why?
| | Humans | 43 | 2023 | 136965 | 0.260 |
Why?
| | Pluripotent Stem Cells | 1 | 2008 | 80 | 0.260 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2022 | 93 | 0.260 |
Why?
| | Cytokines | 3 | 2022 | 2070 | 0.250 |
Why?
| | Fibroblast Growth Factor 2 | 6 | 2009 | 87 | 0.240 |
Why?
| | Liver, Artificial | 4 | 2010 | 5 | 0.230 |
Why?
| | Transplantation, Heterotopic | 2 | 2018 | 18 | 0.230 |
Why?
| | Mice | 23 | 2016 | 17705 | 0.230 |
Why?
| | Hepatocyte Growth Factor | 5 | 2008 | 35 | 0.210 |
Why?
| | Mice, SCID | 8 | 2010 | 368 | 0.210 |
Why?
| | Cell Line, Tumor | 2 | 2010 | 3393 | 0.200 |
Why?
| | Pancreas, Artificial | 3 | 2009 | 83 | 0.180 |
Why?
| | Patient Acuity | 1 | 2022 | 47 | 0.180 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 106 | 0.180 |
Why?
| | Liver Function Tests | 2 | 2020 | 106 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2022 | 508 | 0.170 |
Why?
| | Gastroenterology | 1 | 2023 | 177 | 0.170 |
Why?
| | Stem Cell Transplantation | 4 | 2009 | 177 | 0.170 |
Why?
| | Consensus | 1 | 2023 | 675 | 0.160 |
Why?
| | Choledocholithiasis | 1 | 2020 | 19 | 0.160 |
Why?
| | Gallstones | 1 | 2020 | 33 | 0.160 |
Why?
| | Lithotripsy | 1 | 2020 | 45 | 0.160 |
Why?
| | Brain Diseases | 1 | 2020 | 144 | 0.150 |
Why?
| | End Stage Liver Disease | 1 | 2020 | 81 | 0.150 |
Why?
| | Risk | 1 | 2022 | 901 | 0.150 |
Why?
| | Galactosyltransferases | 1 | 2018 | 11 | 0.150 |
Why?
| | Primates | 1 | 2020 | 139 | 0.150 |
Why?
| | Postoperative Complications | 3 | 2022 | 2622 | 0.150 |
Why?
| | Renal Insufficiency | 1 | 2020 | 160 | 0.140 |
Why?
| | Freund's Adjuvant | 1 | 2018 | 17 | 0.140 |
Why?
| | Gene Knockout Techniques | 1 | 2018 | 118 | 0.140 |
Why?
| | Retrospective Studies | 5 | 2022 | 15536 | 0.140 |
Why?
| | Lithiasis | 1 | 2017 | 3 | 0.140 |
Why?
| | Aftercare | 1 | 2020 | 208 | 0.140 |
Why?
| | Postoperative Care | 1 | 2020 | 255 | 0.140 |
Why?
| | Cell Line | 6 | 2010 | 2855 | 0.140 |
Why?
| | Neovascularization, Physiologic | 3 | 2009 | 179 | 0.140 |
Why?
| | Preoperative Care | 1 | 2020 | 348 | 0.130 |
Why?
| | Ammonia | 6 | 2007 | 62 | 0.130 |
Why?
| | Cells, Cultured | 6 | 2013 | 4136 | 0.130 |
Why?
| | Mycoplasma ovipneumoniae | 1 | 2016 | 1 | 0.130 |
Why?
| | Peptide Elongation Factor Tu | 1 | 2016 | 5 | 0.130 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 1999 | 0.130 |
Why?
| | Endoscopy, Digestive System | 1 | 2017 | 135 | 0.130 |
Why?
| | Lymphocyte Depletion | 1 | 2016 | 136 | 0.120 |
Why?
| | Transplantation Tolerance | 1 | 2016 | 38 | 0.120 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2016 | 73 | 0.120 |
Why?
| | Microscopy, Electron, Transmission | 4 | 2009 | 157 | 0.120 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2016 | 56 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2018 | 4276 | 0.120 |
Why?
| | Antibodies, Heterophile | 1 | 2015 | 13 | 0.120 |
Why?
| | Lidocaine | 5 | 2006 | 39 | 0.120 |
Why?
| | Albumins | 5 | 2007 | 116 | 0.120 |
Why?
| | Treatment Outcome | 7 | 2020 | 10664 | 0.120 |
Why?
| | Immunosuppressive Agents | 2 | 2017 | 861 | 0.120 |
Why?
| | Health Status Indicators | 1 | 2016 | 168 | 0.120 |
Why?
| | alpha-Fetoproteins | 1 | 2015 | 40 | 0.110 |
Why?
| | Activins | 4 | 2008 | 28 | 0.110 |
Why?
| | Neoplastic Stem Cells | 2 | 2010 | 399 | 0.110 |
Why?
| | Oligopeptides | 2 | 2007 | 269 | 0.110 |
Why?
| | Severity of Illness Index | 1 | 2022 | 2809 | 0.110 |
Why?
| | Mice, Inbred BALB C | 7 | 2016 | 1256 | 0.110 |
Why?
| | Exosomes | 1 | 2015 | 104 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2016 | 384 | 0.100 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 83 | 0.100 |
Why?
| | Nanofibers | 2 | 2010 | 21 | 0.100 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2008 | 3661 | 0.100 |
Why?
| | Macrophage-1 Antigen | 1 | 2013 | 28 | 0.100 |
Why?
| | Skin | 1 | 2018 | 746 | 0.100 |
Why?
| | Coculture Techniques | 3 | 2010 | 240 | 0.100 |
Why?
| | Immune Tolerance | 1 | 2015 | 363 | 0.100 |
Why?
| | Female | 14 | 2022 | 73002 | 0.100 |
Why?
| | Cell Proliferation | 3 | 2010 | 2456 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2016 | 420 | 0.090 |
Why?
| | Myeloid Cells | 1 | 2013 | 149 | 0.090 |
Why?
| | Apoptosis | 4 | 2010 | 2542 | 0.090 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2015 | 353 | 0.090 |
Why?
| | Microscopy, Electron, Scanning | 3 | 2006 | 198 | 0.090 |
Why?
| | Embryonic Induction | 2 | 2008 | 31 | 0.090 |
Why?
| | Gelatin | 2 | 2009 | 53 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2010 | 382 | 0.090 |
Why?
| | Time Factors | 4 | 2010 | 6786 | 0.090 |
Why?
| | Immunity, Innate | 2 | 2015 | 819 | 0.080 |
Why?
| | AC133 Antigen | 1 | 2010 | 19 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2010 | 83 | 0.080 |
Why?
| | Alkaline Phosphatase | 2 | 2008 | 149 | 0.080 |
Why?
| | Stromal Cells | 1 | 2010 | 110 | 0.080 |
Why?
| | Polytetrafluoroethylene | 2 | 2007 | 23 | 0.080 |
Why?
| | Cell Line, Transformed | 2 | 2007 | 144 | 0.080 |
Why?
| | Male | 11 | 2022 | 67386 | 0.080 |
Why?
| | Prospective Studies | 1 | 2022 | 7512 | 0.080 |
Why?
| | Insulin | 4 | 2008 | 2394 | 0.080 |
Why?
| | Adult | 5 | 2022 | 37715 | 0.080 |
Why?
| | Injections, Intramuscular | 1 | 2009 | 129 | 0.080 |
Why?
| | Organoids | 1 | 2010 | 112 | 0.080 |
Why?
| | Mice, Inbred C57BL | 3 | 2016 | 5733 | 0.080 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2015 | 604 | 0.070 |
Why?
| | Nanotechnology | 1 | 2009 | 123 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2015 | 748 | 0.070 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2009 | 80 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 677 | 0.070 |
Why?
| | Endoderm | 1 | 2008 | 20 | 0.070 |
Why?
| | Nanog Homeobox Protein | 1 | 2008 | 13 | 0.070 |
Why?
| | Abdomen | 1 | 2009 | 126 | 0.070 |
Why?
| | Drug Discovery | 1 | 2009 | 144 | 0.070 |
Why?
| | Culture Media, Serum-Free | 1 | 2008 | 46 | 0.070 |
Why?
| | Octamer Transcription Factor-3 | 1 | 2008 | 18 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2010 | 1747 | 0.070 |
Why?
| | Middle Aged | 5 | 2022 | 33226 | 0.070 |
Why?
| | Japan | 1 | 2008 | 120 | 0.070 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 112 | 0.070 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1975 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2156 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2010 | 862 | 0.070 |
Why?
| | Survival Rate | 3 | 2020 | 1882 | 0.070 |
Why?
| | Organ Preservation | 1 | 2008 | 103 | 0.070 |
Why?
| | Phenotype | 3 | 2010 | 3148 | 0.070 |
Why?
| | Survival Analysis | 4 | 2016 | 1278 | 0.060 |
Why?
| | Polyurethanes | 1 | 2007 | 38 | 0.060 |
Why?
| | Bioartificial Organs | 1 | 2006 | 3 | 0.060 |
Why?
| | Fibroblast Growth Factors | 1 | 2008 | 176 | 0.060 |
Why?
| | Rats | 5 | 2017 | 5544 | 0.060 |
Why?
| | Membranes, Artificial | 1 | 2006 | 69 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2008 | 1085 | 0.060 |
Why?
| | Genetic Enhancement | 1 | 2005 | 5 | 0.060 |
Why?
| | Bone Regeneration | 1 | 2006 | 25 | 0.060 |
Why?
| | Bone Substitutes | 1 | 2006 | 27 | 0.060 |
Why?
| | Pancreas | 1 | 2008 | 320 | 0.060 |
Why?
| | Totipotent Stem Cells | 1 | 2005 | 1 | 0.060 |
Why?
| | Glucose | 2 | 2008 | 1029 | 0.060 |
Why?
| | Bone Transplantation | 1 | 2006 | 87 | 0.060 |
Why?
| | Delayed-Action Preparations | 1 | 2006 | 173 | 0.060 |
Why?
| | Skull | 1 | 2006 | 145 | 0.060 |
Why?
| | Nanostructures | 1 | 2006 | 109 | 0.060 |
Why?
| | Aged | 2 | 2022 | 23803 | 0.060 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 566 | 0.050 |
Why?
| | Homeodomain Proteins | 1 | 2008 | 506 | 0.050 |
Why?
| | Peptide Fragments | 1 | 2008 | 690 | 0.050 |
Why?
| | Gene Transfer Techniques | 1 | 2005 | 174 | 0.050 |
Why?
| | Biomarkers, Tumor | 1 | 2010 | 1229 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 449 | 0.050 |
Why?
| | Mexico | 1 | 2023 | 231 | 0.050 |
Why?
| | Pregnancy | 1 | 2015 | 6736 | 0.050 |
Why?
| | Knowledge | 1 | 2022 | 56 | 0.050 |
Why?
| | Hyperplasia | 1 | 2022 | 175 | 0.050 |
Why?
| | Immunoglobulin G | 2 | 2017 | 892 | 0.050 |
Why?
| | Diazepam | 3 | 2007 | 33 | 0.050 |
Why?
| | Extracellular Matrix | 1 | 2006 | 532 | 0.040 |
Why?
| | Diabetes Mellitus | 2 | 2008 | 1056 | 0.040 |
Why?
| | Fibroblasts | 1 | 2006 | 997 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2006 | 784 | 0.040 |
Why?
| | Cell Survival | 3 | 2010 | 1124 | 0.040 |
Why?
| | Muscle, Skeletal | 1 | 2009 | 1712 | 0.040 |
Why?
| | Sus scrofa | 2 | 2010 | 53 | 0.040 |
Why?
| | Adult Stem Cells | 2 | 2008 | 40 | 0.030 |
Why?
| | Gene Expression | 3 | 2008 | 1480 | 0.030 |
Why?
| | Endoscopy | 1 | 2020 | 310 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 1251 | 0.030 |
Why?
| | Receptors, CCR4 | 1 | 2016 | 23 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2017 | 60 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 187 | 0.030 |
Why?
| | Cross Reactions | 1 | 2016 | 130 | 0.030 |
Why?
| | Diphtheria Toxin | 1 | 2016 | 66 | 0.030 |
Why?
| | Immunotoxins | 1 | 2016 | 56 | 0.030 |
Why?
| | Interleukin-5 | 1 | 2016 | 41 | 0.030 |
Why?
| | Endothelial Progenitor Cells | 1 | 2016 | 20 | 0.030 |
Why?
| | Spleen | 2 | 2010 | 514 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 971 | 0.030 |
Why?
| | Interleukin-12 | 1 | 2016 | 120 | 0.030 |
Why?
| | Blood Vessels | 2 | 2009 | 182 | 0.030 |
Why?
| | Skin Transplantation | 1 | 2016 | 82 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2016 | 213 | 0.030 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2016 | 67 | 0.030 |
Why?
| | Diagnosis | 1 | 2015 | 14 | 0.030 |
Why?
| | Critical Care | 1 | 2020 | 599 | 0.030 |
Why?
| | Reoperation | 1 | 2017 | 567 | 0.030 |
Why?
| | Immunity, Cellular | 1 | 2016 | 267 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 264 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 850 | 0.030 |
Why?
| | Cell Division | 2 | 2006 | 789 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 868 | 0.030 |
Why?
| | Actins | 2 | 2006 | 415 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2017 | 1343 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 554 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2016 | 782 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 407 | 0.020 |
Why?
| | Neoplasms | 1 | 2008 | 2698 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2016 | 781 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2014 | 333 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2016 | 1229 | 0.020 |
Why?
| | Hospitalization | 1 | 2020 | 2182 | 0.020 |
Why?
| | Implants, Experimental | 1 | 2010 | 21 | 0.020 |
Why?
| | Bioengineering | 1 | 2010 | 20 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2016 | 1151 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1412 | 0.020 |
Why?
| | Endotoxemia | 1 | 2010 | 85 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2010 | 2574 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 2999 | 0.020 |
Why?
| | Glucocorticoid-Induced TNFR-Related Protein | 1 | 2008 | 5 | 0.020 |
Why?
| | Rats, Inbred Lew | 1 | 2009 | 113 | 0.020 |
Why?
| | Regeneration | 1 | 2010 | 197 | 0.020 |
Why?
| | Fetal Stem Cells | 1 | 2008 | 8 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2008 | 433 | 0.020 |
Why?
| | Biomedical Engineering | 1 | 2008 | 27 | 0.020 |
Why?
| | Carbon Tetrachloride | 1 | 2008 | 13 | 0.020 |
Why?
| | Hepatic Artery | 1 | 2008 | 56 | 0.020 |
Why?
| | Cell Lineage | 1 | 2009 | 352 | 0.020 |
Why?
| | Regenerative Medicine | 1 | 2008 | 50 | 0.020 |
Why?
| | Transplantation, Isogeneic | 1 | 2007 | 16 | 0.020 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 10 | 0.020 |
Why?
| | Transcription Factors | 2 | 2006 | 1705 | 0.020 |
Why?
| | Annexin A5 | 1 | 2007 | 25 | 0.020 |
Why?
| | Materials Testing | 1 | 2009 | 349 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2008 | 596 | 0.020 |
Why?
| | Retroviridae | 1 | 2007 | 102 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2010 | 878 | 0.020 |
Why?
| | Portal Vein | 1 | 2008 | 118 | 0.020 |
Why?
| | NF-kappa B | 1 | 2010 | 676 | 0.020 |
Why?
| | Dexamethasone | 1 | 2008 | 359 | 0.020 |
Why?
| | Risk Factors | 1 | 2020 | 10363 | 0.020 |
Why?
| | Integrases | 1 | 2007 | 120 | 0.020 |
Why?
| | Sp7 Transcription Factor | 1 | 2006 | 7 | 0.020 |
Why?
| | Tissue Survival | 1 | 2006 | 18 | 0.020 |
Why?
| | Tamoxifen | 1 | 2007 | 201 | 0.020 |
Why?
| | Haplorhini | 1 | 2006 | 51 | 0.020 |
Why?
| | Ganciclovir | 1 | 2006 | 50 | 0.020 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2006 | 40 | 0.020 |
Why?
| | Blood Glucose | 2 | 2006 | 2184 | 0.020 |
Why?
| | Glycogen | 1 | 2006 | 54 | 0.020 |
Why?
| | Urethane | 1 | 2006 | 43 | 0.020 |
Why?
| | Polyamines | 1 | 2006 | 43 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 232 | 0.020 |
Why?
| | Recombination, Genetic | 1 | 2007 | 207 | 0.010 |
Why?
| | Textiles | 1 | 2006 | 22 | 0.010 |
Why?
| | Mitochondria, Liver | 1 | 2006 | 70 | 0.010 |
Why?
| | Urea | 1 | 2006 | 79 | 0.010 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2005 | 14 | 0.010 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2005 | 15 | 0.010 |
Why?
| | Coated Materials, Biocompatible | 1 | 2006 | 64 | 0.010 |
Why?
| | Serum Albumin | 1 | 2006 | 149 | 0.010 |
Why?
| | Collagen Type I | 1 | 2006 | 137 | 0.010 |
Why?
| | Tissue Culture Techniques | 1 | 2005 | 79 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 234 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2463 | 0.010 |
Why?
| | Glucose Tolerance Test | 1 | 2006 | 367 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2006 | 465 | 0.010 |
Why?
| | Tissue Donors | 1 | 2007 | 412 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2005 | 321 | 0.010 |
Why?
| | Laparoscopy | 1 | 2008 | 434 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2005 | 337 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1706 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2015 | 0.010 |
Why?
| | Genetic Variation | 1 | 2005 | 1000 | 0.010 |
Why?
| | Models, Biological | 1 | 2006 | 1780 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2006 | 2788 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1472 | 0.010 |
Why?
| | Mutation | 1 | 2006 | 3975 | 0.010 |
Why?
| | Child | 1 | 2005 | 21760 | 0.000 |
Why?
|
|
Navarro Alvarez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|